ID   KNS-89
AC   CVCL_2800
SY   KN-S89; KNS89
DR   BioSample; SAMN03151976
DR   cancercelllines; CVCL_2800
DR   CGH-DB; 147-1
DR   Cosmic; 687576
DR   IARC_TP53; 21438
DR   JCRB; IFO50360
DR   Wikidata; Q54900255
RX   CelloPub=CLPUB00152;
RX   PubMed=16232199;
RX   PubMed=20143388;
RX   PubMed=22570425;
WW   https://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a U-251MG derivative (PubMed=20143388; PubMed=22570425). Originally thought to originate from a 66 year old male patient with a gliosarcoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00323.
CC   Population: Caucasian.
CC   Doubling time: 42 hours (CelloPub=CLPUB00152).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Discontinued: JCRB; IFO50360; true.
CC   Derived from site: In situ; Brain, parietal lobe; UBERON=UBERON_0001872.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,11
ST   D16S539: 12
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0021 ! U-251MG
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   CelloPub=CLPUB00152;
RA   Takeshita I., Takaki T., Nakamura T., Maeyama R., Fukui M.,
RA   Kitamura K.;
RT   "Established cell lines derived from human gliomas.";
RL   Hum. Cell 3:255-256(1990).
//
RX   PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x;
RA   Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T.,
RA   Aoyagi M., Ohno K., Imoto I., Inazawa J.;
RT   "Overexpressed Skp2 within 5p amplification detected by array-based
RT   comparative genomic hybridization is associated with poor prognosis of
RT   glioblastomas.";
RL   Cancer Sci. 96:676-683(2005).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//